Inventor · disambiguated record
Alexey Teplyakov
Also filed as: TEPLYAKOV ALEXEY · TEPLYAKOV ALEXEY V
32 granted patents·13 pending applications·191 citations·filing 2007–2023
97Inventor score
Files withJANSSEN BIOTECH INC27CUNNINGHAM MARK7JANSSEN PHARMACEUTICA NV3BLAKE SIMON2SWANSON RONALD V2
Top patents by PatentIndex Score
45 records- 0196US9102737B2Human anti-CD27 antibodies, methods and usesJANSSEN BIOTECH INC·Filed 2013·Granted Aug 11, 2015·36 cites·16 claims
- 0292US10562968B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Feb 18, 2020·18 cites·19 claims
- 0392US9850310B2CD123 binding agents and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Dec 26, 2017·23 cites·20 claims
- 0491US9522957B2Method of treating an inflammatory condition by administering toll-like 3 receptor antagonistsJANSSEN BIOTECH INC·Filed 2013·Granted Dec 20, 2016·10 cites·7 claims
- 0590US9683046B2Nucleic acid molecules encoding anti-CD27 antibodiesJANSSEN BIOTECH INC·Filed 2015·Granted Jun 20, 2017·7 cites·20 claims
- 0690US9481731B2Toll-like receptor 3 antagonistsJANSSEN BIOTECH INC·Filed 2013·Granted Nov 1, 2016·9 cites·10 claims
- 0790US9255153B2Polynucleotides encoding Toll-Like Receptor 3 antagonistsCUNNINGHAM MARK·Filed 2013·Granted Feb 9, 2016·10 cites·9 claims
- 0889US11884722B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN BIOTECH INC·Filed 2023·Granted Jan 30, 2024·1 cites·25 claims
- 0989US8951525B2Human tissue factor antibody and uses thereofJANSSEN BIOTECH INC·Filed 2013·Granted Feb 10, 2015·11 cites·17 claims
- 1089US8722044B2Human tissue factor antibody and uses thereofALMAGRO JUAN CARLOS·Filed 2012·Granted May 13, 2014·12 cites·19 claims
- 1188US8999333B2Human tissue factor antibody and uses thereofJANSSEN BIOTECH INC·Filed 2014·Granted Apr 7, 2015·9 cites·15 claims
- 1287US8399630B2Engineered anti-IL-13 antibodies, compositions, methods and usesSWANSON RONALD V·Filed 2009·Granted Mar 19, 2013·11 cites·5 claims
- 1386US10844122B2Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereofJANSSEN BIOTECH INC·Filed 2016·Granted Nov 24, 2020·4 cites·8 claims
- 1485US2024141055A1Human Anti-CD27 AntibodiesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1584US11414484B2Anti-CCL17 antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Aug 16, 2022·1 cites·12 claims
- 1684US10669343B2Anti-CD154 antibodies and methods of using themJANSSEN BIOTECH INC·Filed 2016·Granted Jun 2, 2020·3 cites·66 claims
- 1784US10301392B2Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodiesJANSSEN BIOTECH INC·Filed 2017·Granted May 28, 2019·3 cites·5 claims
- 1883US8323646B2Engineered anti-IL-13 antibodies, compositions, methods and usesSWANSON RONALD V·Filed 2009·Granted Dec 4, 2012·7 cites·3 claims
- 1982US9238693B2Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodiesCUNNINGHAM MARK·Filed 2013·Granted Jan 19, 2016·3 cites·9 claims
- 2081US11685777B2Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Jun 27, 2023·1 cites·9 claims
- 2180US11787875B2Materials and methods for improved single chain variable fragmentsJANSSEN BIOTECH INC·Filed 2020·Granted Oct 17, 2023·1 cites·26 claims
- 2280US8409567B2Toll-like receptor 3 antagonistsCUNNINGHAM MARK·Filed 2009·Granted Apr 2, 2013·2 cites·17 claims
- 2379US9944697B2Anti-CCL17 antibodiesJANSSEN BIOTECH INC·Filed 2014·Granted Apr 17, 2018·1 cites·8 claims
- 2478US9932404B2Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonistJANSSEN BIOTECH INC·Filed 2016·Granted Apr 3, 2018·1 cites·18 claims
- 2578US8540986B2Toll-like receptor 3 antagonistsCUNNINGHAM MARK·Filed 2010·Granted Sep 24, 2013·2 cites·9 claims
- 2678US2024343796A1Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 2776US10829549B2Anti-CCL17 antibodiesJANNSEN BIOTECH INC·Filed 2017·Granted Nov 10, 2020·1 cites·7 claims
- 2875US2022348647A1Anti-ccl17 antibodiesJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2973US11732050B2Neutralizing human anti-CD27 antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Aug 22, 2023·0 cites·7 claims
- 3073US8460659B2Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseasesCUNNINGHAM MARK·Filed 2011·Granted Jun 11, 2013·2 cites·5 claims
- 3171US10562948B2GM-CSF variants and methods of useJANSSEN BIOTECH INC·Filed 2017·Granted Feb 18, 2020·1 cites·6 claims
- 3271US10544229B2Agonistic antibodies specifically binding CD40 and methods of useJANSSEN BIOTECH INC·Filed 2016·Granted Jan 28, 2020·1 cites·45 claims
- 3369US10689453B2Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodiesJANSSEN BIOTECH INC·Filed 2019·Granted Jun 23, 2020·0 cites·5 claims
- 3469US2024067754A1Materials and methods for improved single chain variable fragmentsJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 3566US2018179294A1Toll-like receptor 3 antagonistsJANSSEN BIOTECH INC·Filed 2018·Application pending·0 cites
- 3661US11208450B2GM-CSF variants and methods of useJANSSEN BIOTECH INC·Filed 2020·Granted Dec 28, 2021·0 cites·5 claims
- 3759US11421037B2Nucleic acids encoding anti-CD154 antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Aug 23, 2022·0 cites·25 claims
- 3858US2025145716A1Anti- programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of useRAKUTEN MEDICAL INC·Filed 2023·Application pending·0 cites
- 3957US2025320304A1Compositions comprising enhanced multispecific binding agents for an immune responseJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 4049US2014017250A1Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular DiseasesCUNNINGHAM MARK·Filed 2013·Application pending·0 cites
- 4149US2009162375A1Resistin antagonists and their useBLAKE SIMON·Filed 2007·Application pending·0 cites
- 4242US2009117122A1Resistin Antagonists and Their UseCARTON JILL·Filed 2008·Application pending·0 cites
- 4341US2013090457A1Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular DiseasesCUNNINGHAM MARK·Filed 2012·Application pending·0 cites
- 4437US2017210799A1Anti-ror1, antibodies, ror1 x cd3 bispecific antibodies, and methods of using the sameJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 4536US2011071277A1Resistin antagonists and their useBLAKE SIMON·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexey Teplyakov files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →